Vanguard Group Inc Keros Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,631,648 shares of KROS stock, worth $36.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,631,648
Previous 2,566,321
2.55%
Holding current value
$36.1 Million
Previous $26.2 Million
34.35%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding KROS
# of Institutions
156Shares Held
38.6MCall Options Held
834KPut Options Held
969K-
Adar1 Capital Management, LLC Austin, TX5.39MShares$73.9 Million11.03% of portfolio
-
Madison Avenue Partners, LP New York, NY2.69MShares$36.9 Million3.85% of portfolio
-
Jpmorgan Chase & CO New York, NY2.6MShares$35.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.51MShares$34.5 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA2MShares$27.4 Million3.45% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $353M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...